#ESMO26 能否在 MIBC 中通过 EV + P 保留膀胱？@tompowles1 展示了 TiP：EV-209，一项探索无计划 RC 或 RT 的膀胱保留的 II 期试验：
📌 N≈240，全球，单臂研究
📌 符合条件但拒绝根治性膀胱切除术的患者
📌 EV+P 4 个周期，随后进行 MRI/CT、膀胱镜检查伴活检/TURBT 及尿细胞学
📌 达到 cCR 的患者继续治疗（最多 9 个 EV 周期和 17 个 pembrolizumab 周期）
📌 共同主要终点：cCR 率和应答者中 2 年保留膀胱的 EFS
📌 探索性 ctDNA/utDNA MRD 分析
@UroToday @myESMO
355 浏览 · 5 赞 · 3 转发 · 0 回复
NRG-GY020: Phase III randomized trial of radiation +/- MK-3475 (pembrolizumab) for newly diagnosed early-stage high intermediate risk (HIR) mismatch repair deficient (dMMR) endometrioid endometrial cancer
https://esmocongress.esmo.orgSacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgSTARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgEfficacy and safety of lifileucel and pembrolizumab in patients with immune check point inhibitor-naïve advanced melanoma: Final results from IOV-COM-202 study
https://esmocongress.esmo.orgUpdated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
https://esmocongress.esmo.orgFirst-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org来源：Julian Chavarriaga · x.com